Skip to main content

Table 1 Drug toxicity enhancement factors (EF's) obtained in human tumour cell lines when cells were blocked in G2 with irradiation and then subjected to Pentoxifylline and a TC: 05 dose of a cytotoxic drug. Data adapted from [6]

From: Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation

Cell line a

 

Drug

EF's

4197

p53 wt b

D, M, CP

1.3

3.0

2.6

4451

p53 mut b

D, M, CP

2.3

8.6

52

Be11

p53 wtb

D, M, CP

1.4

2.3

1.2

MeWo

p53 mut b

D, M, CP

2.8

85

74

DU 145

p53 mut c

V, E, CP

4.8

1.5

4.1

BM1604

p53 mut c

V, E, CP

2.6

1.0

4.5

LNCaP

p53 wt c

V, E, CP

1.4

1.5

1.6

  1. a) 4197 and 4451 are human squamous carcinoma cell lines. Be-11 and MeWo are human melanoma cell lines. The DU-145 prostatic tumour cell line was established from a metastatic central nervous system lesion. The BM 1604 cell was established from a radical prostatectomy biopsy. The LnCaP cell line was established from a supraclavicular lymph node metatstasis of a human prostate adenocarcinoma.
  2. D: Daunorubicin; E: Etoposide; M: Melphalan; V: Vinblastine; CP: cisplatin based on clonogenic SF 7 (survival fraction at 7 Gy) and dye staining data b) Binder et al. [4] ; c) Serafin et al. [40]